Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

Learn more about prostate cancer and why there is a debate over whether or not patients should get tested for it.

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...

A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

Biden's personal office announced in May that he had been diagnosed with an "aggressive form" of prostate cancer that had ...

Biden’s personal office revealed in May that he had been diagnosed with an “aggressive form” of prostate cancer that had ...